Mupirocin (DB00410): A Comprehensive Monograph on its Chemistry, Pharmacology, and Clinical Utility

Executive Summary

Mupirocin is a topical antibiotic with a unique structure and mechanism of action that has established it as a cornerstone therapy for superficial bacterial skin infections and a critical tool in public health infection control strategies. Derived from the fermentation of Pseudomonas fluorescens, Mupirocin is not a single chemical entity but a mixture of related pseudomonic acids, with pseudomonic acid A being the principal active component. Its defining pharmacological feature is the specific inhibition of bacterial isoleucyl-tRNA synthetase (IleRS), a mechanism distinct from all other major antibiotic classes. This distinction confers the significant clinical advantage of no inherent cross-resistance, allowing Mupirocin to remain effective against pathogens that have developed resistance to other antimicrobials, most notably methicillin-resistant Staphylococcus aureus (MRSA).

The clinical utility of Mupirocin is twofold. It is a first-line treatment for primary skin infections such as impetigo and folliculitis, as well as secondarily infected traumatic skin lesions, caused by susceptible strains of S. aureus and Streptococcus pyogenes. Beyond treating active infections, its role in public health has been profound, particularly through the use of a dedicated nasal formulation for the eradication of MRSA carriage. This application is central to infection control programs aimed at reducing transmission and preventing invasive infections in high-risk settings like hospitals and long-term care facilities.

The therapeutic value of Mupirocin is, however, shadowed by the growing global challenge of bacterial resistance. Two distinct mechanisms threaten its long-term efficacy. Low-level resistance (MuL), arising from chromosomal mutations, poses a potential risk to individual treatment success, particularly in the context of the drug's high protein binding in wound exudate. Of far greater concern is high-level resistance (MuH), which is mediated by the plasmid-borne mupA gene. The horizontal transfer of this plasmid, which often carries resistance determinants to other antibiotic classes, facilitates the rapid spread of multi-drug resistant organisms and is directly linked to the failure of MRSA decolonization efforts. The widespread use of Mupirocin, especially in institutional decolonization protocols, creates significant selective pressure that drives the proliferation of these resistant strains.

From a safety perspective, Mupirocin is exceptionally well-tolerated. Its pharmacokinetic profile is ideal for a topical agent, with minimal systemic absorption, rapid metabolism to an inactive metabolite (monic acid), and swift renal excretion. This profile results in a near-absence of systemic adverse effects and drug interactions. A key formulation-specific precaution relates to the polyethylene glycol (PEG) vehicle present in the ointment formulation, which can be absorbed from large, open wounds or burns and poses a risk of nephrotoxicity in patients with pre-existing moderate to severe renal impairment.

In conclusion, Mupirocin stands as a valuable and effective, yet increasingly vulnerable, therapeutic agent. Its unique mechanism and targeted clinical applications are indispensable in the current era of antimicrobial resistance. However, its continued utility is critically dependent on robust antimicrobial stewardship. Prudent, evidence-based use, coupled with diligent surveillance for resistance, is imperative to preserve the efficacy of this important antibiotic for the future.

Chemical Identity and Physicochemical Properties

A thorough understanding of Mupirocin's chemical nature is fundamental to appreciating its formulation, stability, and biological activity. It is a natural product with a complex structure, existing commercially as a defined mixture rather than a single pure compound.

Nomenclature and Identifiers

Mupirocin is the established generic name for this antibiotic. Historically and in early scientific literature, it was referred to as pseudomonic acid, a name derived from its producing organism, Pseudomonas.[1] Specifically, the primary active component is pseudomonic acid A.[1] Over its development and commercial life, it has been associated with various synonyms and codes, including BRL 4910A, Bactoderm, and Turixin.[1]

Commercially, Mupirocin is most widely recognized by its brand names, which include Bactroban, Bactroban Nasal, and Centany.[1] To facilitate unambiguous identification across scientific and regulatory databases, a standardized set of identifiers is used, as detailed in Table 1.

Chemical Structure and Composition

Mupirocin is classified as a small molecule drug [User Query]. Its molecular formula is C26​H44​O9​, corresponding to a molecular weight of approximately 500.62 g/mol.[1]

The formal IUPAC name for the principal component, pseudomonic acid A, is 9-oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid.[1] This complex name describes a unique structure: an alpha,beta-unsaturated ester resulting from the formal condensation of the carboxylic acid group of monic acid with the terminal hydroxyl group of 9-hydroxynonanoic acid.[9] The structure contains several stereogenic centers, a tetrahydropyran ring, and an epoxide ring, all of which are critical for its biological activity.

A crucial aspect of Mupirocin's chemical identity is that it is not a single, pure substance but a mixture of several structurally related pseudomonic acids produced biosynthetically.[4] The composition is dominated by pseudomonic acid A (PA-A), which constitutes over 90% of the mixture and is the primary source of its antibacterial activity.[2] Several minor, related acids are also present, including [9]:

• Pseudomonic acid B: Contains an additional hydroxyl group at the C8 position.
• Pseudomonic acid C: Features a double bond between C10 and C11, in place of the epoxide ring found in PA-A.
• Pseudomonic acid D: Contains a double bond at the C4' and C5' positions within the 9-hydroxy-nonanoic acid portion of the molecule.

This identity as a controlled, natural-product mixture, rather than a single synthetic molecule, has significant consequences for its production and quality control. The consistency of the mixture's profile, particularly the high percentage of the active PA-A component, is a critical quality attribute. Regulatory agencies monitor this closely, and failure to meet the specified assay for the active ingredient can lead to product recalls, as has been documented.[14] This underscores the importance of rigorous manufacturing standards to ensure consistent potency and efficacy from batch to batch, a challenge inherent to drugs derived from fermentation processes.

Physical and Chemical Properties

Mupirocin presents as a white to almost-white crystalline solid or powder.[8] Its key physicochemical properties are summarized in Table 1. The melting point is consistently reported in the range of 74–78 °C.[1] It has a high boiling point of 672.3°C at standard pressure.[1]

Mupirocin's solubility profile dictates its formulation for topical use. It is poorly soluble in water but demonstrates good solubility in various organic solvents, including dimethyl sulfoxide (DMSO), ethanol, and methanol.[1] This lipophilicity is consistent with its ability to be formulated in ointment and cream bases for effective delivery into the skin.

The compound requires careful handling and storage conditions. It is sensitive to heat, air, and moisture (hygroscopic) and should be stored under inert gas at refrigerated (2-8°C) or frozen (<0°C) temperatures to prevent degradation and ensure stability.[1]

Table 1: Chemical and Physical Properties of Mupirocin

Property	Value	Source(s)
DrugBank ID	DB00410	9
Type	Small Molecule	[User Query]
CAS Number	12650-69-0	1
Molecular Formula	C26​H44​O9​	1
Molecular Weight	500.62 g/mol	1
IUPAC Name	9-oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid	1
Appearance	White to almost-white crystalline powder	8
Melting Point	77–78 °C	8
Boiling Point	672.3°C at 760 mmHg	1
Solubility	Poorly soluble in water; Soluble in DMSO, Ethanol, Methanol	1
Storage Conditions	Store at 2-8°C or <0°C; Air, heat, and moisture sensitive	1

History, Production, and Regulatory Milestones

The history of Mupirocin is a compelling narrative of natural product discovery, intricate biosynthetic elucidation, and strategic clinical development that positioned it as a key agent in the fight against antimicrobial resistance.

Discovery and Development

Mupirocin's story begins in the laboratory with the isolation of a unique antibacterial substance from the Gram-negative soil bacterium Pseudomonas fluorescens, specifically strain NCIMB 10586.[1] The initial work, conducted in the early 1970s, led to the characterization of the primary active compound, named pseudomonic acid A, by a team led by A. T. Fuller in 1971.[2] The drug was subsequently developed and first brought to market by GlaxoSmithKline under the well-known trade name Bactroban.[2]

Biosynthesis and Production

Mupirocin is a product of microbial fermentation, not chemical synthesis, and its production pathway is a showcase of enzymatic complexity.[8]

Genetic and Enzymatic Framework

The blueprint for Mupirocin synthesis is encoded within a massive 74 kb gene cluster. This cluster directs the expression of six large, multi-domain enzymes and at least twenty-six other specialized peptides that work in concert.[9] The synthesis is carried out by a hybrid Type I and Type II polyketide synthase (PKS) system, a molecular assembly line that builds the complex carbon skeleton of the molecule. A particularly noteworthy feature is its atypical

trans-acyltransferase (AT) organization. In most Type I PKS systems, each module has its own integrated AT domain to load the next building block. In the Mupirocin pathway, however, this function is consolidated into a single, separate protein, MmpC, which contains the only two AT domains for the entire multi-protein complex. This trans-acting system services the other PKS proteins, MmpA and MmpD, which lack AT domains entirely.[9]

Molecular Assembly

The final Mupirocin molecule is constructed via the esterification of two major precursors, each synthesized on its own dedicated enzymatic track [9]:

1. Monic Acid Synthesis: This 17-carbon polyketide forms the core of the molecule. Its synthesis is initiated on the MmpD protein complex and completed on MmpA. The process involves multiple cycles of chain extension using malonyl-CoA as a building block, along with precise modifications such as methylation and ketoreduction at specific positions.[9]
2. 9-Hydroxynonanoic Acid (9-HN) Synthesis: This 9-carbon fatty acid chain is believed to be synthesized by the MmpB protein complex.[9]

Once the main chains are assembled, the molecule undergoes a series of crucial "tailoring" steps, including the enzymatic formation of the tetrahydropyran ring and the epoxide group, which are mediated by specialized enzymes such as MupW and MupO.[9] The entire production process is tightly regulated within the bacterium by a quorum-sensing system, which uses signaling molecules to coordinate gene expression based on cell population density.[19]

Commercial Production

Commercial-scale production of Mupirocin relies on a controlled submerged fermentation process using P. fluorescens.[16] The bacteria are cultured in a specialized nutrient-rich medium (e.g., SSM broth) under optimized conditions of temperature and aeration to maximize yield.[19] Following fermentation, the Mupirocin is extracted from the culture supernatant, typically using an organic solvent like ethyl acetate. The crude extract then undergoes extensive purification, primarily through techniques like high-performance liquid chromatography (HPLC), to isolate the final product with the required purity and composition.[19]

Regulatory History and FDA Approval

The regulatory journey of Mupirocin in the United States reveals a strategic, phased introduction of different formulations designed to meet evolving clinical needs. This timeline is not arbitrary but rather reflects the shifting landscape of infectious diseases, particularly the emergence and spread of MRSA as a major public health threat.

The initial FDA approval was granted on December 31, 1987, for Bactroban (mupirocin) 2% topical ointment.[20] This established its foundational role as a treatment for common superficial skin infections like impetigo.

A pivotal moment in its history came on September 18, 1995, with the approval of Bactroban Nasal (mupirocin calcium) 2% ointment.[20] This approval was a direct response to the growing crisis of hospital-acquired MRSA in the 1990s. The development of a formulation specifically for eradicating nasal carriage demonstrated a strategic shift in the drug's application from merely treating infections to preventing them in high-risk populations, solidifying its importance in infection control.

Subsequently, on December 11, 1997, the FDA approved Bactroban (mupirocin calcium) 2% cream.[20] This provided a valuable alternative to the oleaginous ointment base. The cream formulation is more cosmetically acceptable, especially for facial lesions, potentially improving patient adherence. Furthermore, it offered a formulation free of the polyethylene glycol (PEG) vehicle, an important clinical distinction for certain patient populations. While some sources incorrectly cite 1997 as the initial approval date for Mupirocin as a whole, this date specifically marks the introduction of the cream formulation.[17]

Following the expiration of patents, generic versions of Mupirocin have become available, with approvals for products like a generic Mupirocin Cream occurring on January 24, 2013.[24] The staggered approval history thus tells a story of a drug that evolved from a standard topical antibiotic to a critical tool in hospital epidemiology, and finally to a more refined set of therapeutic options for clinicians.

Table 2: FDA Approval History of Mupirocin Formulations

Formulation	Active Ingredient	Brand Name (Applicant)	Approval Date	Source(s)
Topical Ointment, 2%	Mupirocin	Bactroban (GlaxoSmithKline)	December 31, 1987	20
Nasal Ointment, 2%	Mupirocin Calcium	Bactroban (GlaxoSmithKline)	September 18, 1995	20
Topical Cream, 2%	Mupirocin Calcium	Bactroban (GlaxoSmithKline)	December 11, 1997	20

Pharmacology

The pharmacological profile of Mupirocin is characterized by a potent, unique mechanism of local antibacterial action combined with a pharmacokinetic profile that ensures minimal systemic exposure, creating a highly effective and safe topical agent.

Pharmacodynamics: Mechanism of Action

Mupirocin's antibacterial effect stems from a mechanism that is distinct among all other clinically utilized antibiotic classes. It functions as a potent, reversible, and highly specific inhibitor of bacterial isoleucyl-tRNA synthetase (IleRS).[1] This enzyme plays an indispensable role in the first step of protein synthesis: the charging of transfer RNA (tRNA) with the amino acid isoleucine.

By binding to IleRS, Mupirocin competitively blocks the formation of isoleucyl-tRNA.[3] This action leads to a rapid depletion of the charged tRNA pool within the bacterial cell, which in turn halts the incorporation of isoleucine into nascent polypeptide chains. The result is a complete arrest of bacterial protein and RNA synthesis, ultimately leading to cell death.[3] The affinity of Mupirocin for bacterial IleRS is substantially higher than for its mammalian counterpart, which accounts for its selective toxicity against bacteria.[16]

The nature of its activity—bacteriostatic or bactericidal—is concentration-dependent. At the lower concentrations corresponding to its minimum inhibitory concentration (MIC), Mupirocin is primarily bacteriostatic, meaning it inhibits bacterial growth.[2] However, when applied topically as a 2% formulation (20,000 µg/g), it achieves exceptionally high local concentrations at the site of infection. At these levels, its effect becomes robustly bactericidal, capable of killing 90–99% of susceptible bacteria over a 24-hour period.[3] The minimum bactericidal concentration (MBC) is typically 8 to 30 times higher than the MIC, a threshold easily surpassed by standard topical application.[3]

A paramount advantage of this unique mechanism is the absence of inherent cross-resistance with other antibiotic classes. Bacteria resistant to beta-lactams, macrolides, tetracyclines, aminoglycosides, or fluoroquinolones remain fully susceptible to Mupirocin, provided they have not acquired a specific Mupirocin resistance mechanism.[3] This makes it an invaluable agent for treating infections caused by multi-drug resistant organisms like MRSA.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Mupirocin is ideally suited for a topical agent, designed to maximize local activity while minimizing systemic effects. This favorable profile underpins its excellent safety record.

• Absorption: Following dermal application to intact skin, systemic absorption of Mupirocin is negligible, with estimates consistently below 1%.[3] A clinical study involving daily application to a large 400 cm2 area of skin for seven days found that the mean cumulative urinary excretion of its metabolite was only 1.25% of the total applied dose, confirming minimal passage into the bloodstream.[3] However, absorption can be more significant if the drug is applied over large areas of damaged or broken skin, such as extensive burns or open wounds.[3]
• Distribution: In the rare event that Mupirocin reaches the systemic circulation, it is extensively bound to plasma proteins, with a binding percentage greater than 97%.[3] This high degree of protein binding further limits the amount of free, active drug available to act on systemic tissues. Specific data on its volume of distribution are not available.[3]
• Metabolism: Mupirocin that enters the bloodstream is subject to rapid and extensive metabolism, primarily in the liver and blood, into its principal metabolite, monic acid. Monic acid is microbiologically inactive and possesses no antibacterial properties.[3] This rapid inactivation is the primary reason Mupirocin is not suitable for systemic administration.[16]
• Excretion: The inactive monic acid metabolite is efficiently eliminated from the body via renal excretion.[3] The elimination half-life of both the parent drug and its metabolite is very short. Following intravenous administration in clinical studies, the elimination half-life was 20 to 40 minutes for Mupirocin and 30 to 80 minutes for monic acid, ensuring that any absorbed drug is cleared from the body quickly.[3]

This combination of a unique local mechanism and a pharmacokinetic profile that prevents systemic exposure creates a powerful therapeutic synergy. The drug is highly potent where it is needed—on the skin—but is effectively absent systemically, which minimizes the risk of systemic side effects, drug interactions, and the development of resistance in commensal bacteria in other body sites like the gut.

However, a more nuanced analysis reveals how a subtle pharmacokinetic property can influence clinical outcomes. The high protein binding of Mupirocin (>97%) is a critical factor in the context of real-world infections.[3] While laboratory MICs are determined in protein-free media, wound exudate is rich in proteins. This means that at the actual site of infection, a significant fraction of the applied Mupirocin will be bound to proteins and thus rendered inactive. This effectively lowers the free, active drug concentration. While the 2% topical concentration is generally considered high enough to overcome even low-level resistance (MuL), the reduction in free drug due to protein binding may narrow this therapeutic margin. This phenomenon could explain documented cases of clinical failure even against strains classified with only low-level resistance, providing a crucial link between a pharmacokinetic property and the clinical relevance of a specific resistance mechanism.[26]

Microbiology

The clinical utility of Mupirocin is defined by its targeted spectrum of antimicrobial activity and the evolving challenge of bacterial resistance. It is a narrow-spectrum agent with potent activity against the key Gram-positive pathogens of skin and soft tissue.

Antimicrobial Spectrum of Activity

Mupirocin's activity is primarily directed against aerobic Gram-positive cocci, with limited and selective action against some Gram-negative organisms.[15]

Gram-Positive Bacteria

Mupirocin demonstrates excellent in vitro and clinical efficacy against the most common causative agents of superficial skin infections.[3]

• Staphylococcus aureus: Mupirocin is highly active against S. aureus, including strains that are resistant to other antibiotics, such as methicillin-resistant S. aureus (MRSA) and beta-lactamase-producing strains.[15] Minimum inhibitory concentrations (MICs) for susceptible isolates are consistently low, typically ≤0.5 µg/mL.[27]
• Streptococcus pyogenes: Also known as Group A Streptococcus (GAS), this organism is highly susceptible to Mupirocin.[15] Typical MIC values are around 0.12 µg/mL.[34]
• Other Staphylococci and Streptococci: The spectrum includes high activity against coagulase-negative staphylococci such as Staphylococcus epidermidis.[3] It is also active against other beta-hemolytic streptococci (Lancefield groups B, C, and G) and Streptococcus pneumoniae.[15]
• Less Susceptible Gram-Positives: Activity is significantly lower against Enterococcus faecalis (MIC ~64 µg/mL) and some Corynebacterium species (MIC >128 µg/mL).[16]

Gram-Negative Bacteria

Mupirocin's activity against Gram-negative bacteria is limited and species-specific.

• Susceptible Species: It shows good in vitro activity against Haemophilus influenzae and Neisseria gonorrhoeae, with very low MICs of 0.12 µg/mL and 0.05 µg/mL, respectively.[16] It is also active against Neisseria meningitidis, Moraxella catarrhalis, and Pasteurella multocida.[15]
• Resistant Species: The vast majority of Gram-negative bacilli are resistant. This includes common pathogens like Escherichia coli (MIC ~128 µg/mL), Klebsiella pneumoniae, and especially Pseudomonas aeruginosa (MIC >1600 µg/mL).[27]

Other Organisms

Mupirocin has no clinically relevant activity against anaerobic bacteria, such as Bacteroides fragilis or Clostridium difficile (MICs ≥32 µg/mL), nor does it have activity against fungi like Candida albicans.[16]

Table 3: Detailed Antimicrobial Spectrum of Mupirocin with MIC Ranges

Organism	Mupirocin MIC (µg/mL)	Source(s)
Gram-Positive Aerobes
Staphylococcus aureus (incl. MRSA)	≤0.5	27
Staphylococcus epidermidis	≤0.5	27
Streptococcus pyogenes (Group A)	0.12	34
Streptococcus agalactiae (Group B)	0.5	34
Streptococcus pneumoniae	0.12	34
Listeria monocytogenes	8.0	34
Enterococcus faecalis	64	16
Clostridium difficile	32	34
Gram-Negative Aerobes
Haemophilus influenzae	0.12	34
Neisseria gonorrhoeae	0.05	34
Neisseria meningitidis	0.05	34
Moraxella catarrhalis	0.2	34
Escherichia coli	128	34
Pseudomonas aeruginosa	≥6,400	34
Bacteroides fragilis (Anaerobe)	>6,400	34

Bacterial Resistance

The emergence and spread of Mupirocin resistance is the single greatest threat to its continued clinical utility. Resistance rates are rising globally, with some surveillance studies reporting prevalence as high as 81% in certain settings, particularly among MRSA isolates.[3] Two primary mechanisms of resistance have been identified, and they pose distinct levels of clinical and public health challenges.

Mechanisms of Resistance

1. Low-Level Resistance (MuL): This type of resistance is characterized by a moderate increase in MIC values, typically in the range of 8 to 256 µg/mL.[9] MuL arises from one or more point mutations in the organism's native chromosomal gene, ileS, which codes for the target enzyme, isoleucyl-tRNA synthetase.[36] These mutations alter the enzyme's structure, reducing its binding affinity for Mupirocin. The clinical significance of MuL is debated; while the high local drug concentrations from topical application are thought to overcome this level of resistance, treatment failures have been reported, possibly due to factors like high protein binding in wounds that reduce the free drug concentration.[26] This mechanism represents a slower, vertical mode of resistance evolution within a bacterial lineage.
2. High-Level Resistance (MuH): This is a much more serious form of resistance, defined by very high MICs of ≥512 µg/mL, which are well above clinically achievable concentrations.[29] MuH is not caused by a mutation but by the acquisition of an entirely new gene, mupA, which is carried on a mobile genetic element known as a plasmid.[36] This mupA gene encodes a novel, highly resistant version of IleRS that is not effectively inhibited by Mupirocin, allowing the bacterium to synthesize proteins unabated even in the presence of the drug.

Epidemiology and Public Health Implications

The distinction between these two resistance mechanisms is critical from a public health perspective. While MuL is a concern for the treatment of an individual patient, MuH is a driver of epidemic spread and a significant threat to infection control efforts. The mupA gene's location on a plasmid is of paramount concern because plasmids can be transferred horizontally between bacteria, not only within the same species (S. aureus to S. aureus) but also across different species and genera. This allows for the rapid dissemination of high-level resistance throughout a bacterial population, a process far faster than the selection of chromosomal mutations.

Furthermore, the plasmids carrying mupA are often conjugative and carry resistance determinants for multiple other classes of antibiotics, such as tetracycline and trimethoprim.[9] This means that the selective pressure exerted by the widespread use of Mupirocin can inadvertently co-select for bacteria that are resistant to a host of other important drugs, creating multi-drug resistant "superbugs".[35] High-level resistance is unequivocally associated with the failure of MRSA decolonization regimens, undermining a key strategy for preventing serious nosocomial infections.[36] The increasing prevalence of MuH, driven by Mupirocin use, thus poses a substantial threat to both individual patient care and broader public health.

Clinical Applications

Mupirocin's clinical use is centered on its topical application for treating superficial skin infections and for eradicating nasal colonization of S. aureus, particularly MRSA. Its applications are divided into FDA-approved indications and several common off-label uses.

Approved Clinical Indications

The U.S. Food and Drug Administration (FDA) has approved Mupirocin for three primary indications, with specific formulations designated for each use.[38]

Impetigo

Mupirocin 2% ointment is indicated for the topical treatment of impetigo caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes.[7] Impetigo, whether bullous or non-bullous, is a common superficial skin infection, and while it can be self-limiting, antibiotic treatment is typically recommended to shorten the duration of symptoms, reduce transmission to others, and prevent complications.[38] For limited, non-extensive disease, topical therapy with Mupirocin is considered a first-line treatment and has been shown to be as effective as oral antibiotics like erythromycin, with a more favorable side effect profile.[33] Clinical trials have demonstrated high rates of clinical cure and pathogen eradication, often exceeding 90%.[3]

Secondarily Infected Traumatic Skin Lesions

Mupirocin 2% cream is approved for the topical treatment of secondarily infected traumatic skin lesions, such as minor lacerations, sutured wounds, and abrasions (up to 10 cm in length or 100 cm2 in area).[7] These infections are also typically caused by

S. aureus and S. pyogenes. In this setting, Mupirocin provides targeted antibacterial therapy directly at the site of trauma, helping to prevent the progression to more serious infections like cellulitis. Clinical studies have shown that Mupirocin cream is as effective as oral cephalexin for these infections, again with the benefit of fewer systemic adverse effects.[41]

Nasal Carriage of Staphylococcus aureus

Mupirocin calcium 2% nasal ointment is specifically indicated for the eradication of nasal colonization with MRSA in adult patients and healthcare workers.[38] This indication is a cornerstone of infection control programs designed to reduce the risk of MRSA transmission and infection during institutional outbreaks.[33] The anterior nares are the primary reservoir for

S. aureus in the human body, and decolonizing this site in carriers can significantly decrease the risk of subsequent autoinfection (e.g., surgical site infections) and transmission to other vulnerable patients.[42] Completed Phase 3 clinical trials have confirmed the efficacy of Mupirocin for the prevention of recurrent MRSA skin infections through decolonization protocols.[44] However, one trial comparing Mupirocin to another agent for MRSA decolonization was withdrawn, indicating ongoing research in this area.[45]

Off-Label Uses

In addition to its approved indications, Mupirocin is frequently used off-label for a variety of other dermatological conditions and infection control purposes.[38]

• Other Superficial Skin Infections: It is commonly used for other primary and secondary skin infections, including folliculitis, furunculosis (boils), and infected eczema or atopic dermatitis.[33]
• Minor Wounds, Burns, and Ulcers: Clinicians may prescribe Mupirocin for minor infected burns, wounds, or ulcers to control local bacterial growth.[38] However, it is not recommended for preventing surgical site infections by applying it to clean surgical wounds.[38]
• MSSA Nasal Decolonization: The nasal ointment is often used off-label to eradicate nasal carriage of methicillin-susceptible S. aureus (MSSA) in addition to MRSA, particularly in pre-operative settings for high-risk surgical patients (e.g., cardiac or orthopedic surgery) to reduce the risk of postoperative staphylococcal infections.[33]
• Decolonization in Other High-Risk Groups: Use has been extended to other high-risk patient populations, such as those on dialysis, in intensive care units (ICUs), or in long-term care facilities, to reduce the burden of S. aureus colonization and infection.[38]

While these off-label uses are common, experts caution against the routine, indiscriminate use of Mupirocin for colonization eradication due to the significant risk of promoting resistance. A targeted strategy based on screening and risk assessment is generally preferred over widespread decolonization.[38]

Dosage, Administration, and Formulations

Mupirocin is available for prescription use exclusively as a topical product, formulated at a 2% concentration in several different bases to suit various clinical applications.[46]

Dosage Forms and Strengths

Mupirocin is commercially available in the United States in two primary dosage forms [7]:

• Topical Ointment: Mupirocin 2% (20 mg of Mupirocin per gram). This is typically supplied in a polyethylene glycol (PEG) base.[15]
• Topical Cream: Mupirocin calcium 2% (equivalent to 20 mg Mupirocin per gram). This is supplied in a water-miscible, oil-in-water cream base that does not contain PEG.[24]
• Nasal Ointment: Mupirocin calcium 2% (equivalent to 20 mg Mupirocin per gram). This formulation is specifically designed for intranasal application.[20]

The products are available under various brand names, including Bactroban and Centany, and also as generic formulations.[5] They are typically packaged in 15 g, 22 g, or 30 g tubes.[24]

Administration Guidelines

Proper administration is crucial for efficacy and to minimize potential side effects. Mupirocin is for external use only and must not be ingested or used ophthalmically.[7]

Topical Cream and Ointment

• Application: The affected skin area should first be cleaned and dried thoroughly.[50] A small amount of the cream or ointment should then be applied as a thin film to the affected area.[39]
• Frequency and Duration:
• For Impetigo (Ointment): Apply three times daily. The typical duration of therapy is 7 to 14 days, though some regimens may be as short as 5 days.[7]
• For Secondarily Infected Lesions (Cream): Apply three times daily for 10 days.[7]
• Occlusion: The treated area may be covered with a sterile gauze dressing if desired.[7]
• General Precautions: Contact with the eyes, nose (unless using the nasal formulation), and mouth should be avoided. If accidental contact occurs, the area should be rinsed thoroughly with water.[7] It should not be applied to extensive burns or open wounds unless directed by a physician, due to the risk of PEG absorption from the ointment formulation.[31] Patients should be instructed to complete the full course of therapy even if symptoms improve, to prevent recurrence.[50] If there is no clinical improvement within 3 to 5 days, the patient should be re-evaluated.[7]

Nasal Ointment

• Application: For nasal decolonization, approximately one-half of the ointment from a single-use tube is applied into one nostril, and the other half is applied into the other nostril.[51] After application, the nostrils should be massaged together to spread the ointment throughout the anterior nares.
• Frequency and Duration: The standard regimen is twice daily (morning and evening) for 5 days.[33]

Safety Profile

Mupirocin has an excellent safety profile, characterized by high local tolerability and a near-absence of systemic toxicity, a direct result of its minimal percutaneous absorption. However, specific precautions, contraindications, and potential adverse effects must be considered.

Adverse Effects

Adverse reactions to topical Mupirocin are generally mild, localized to the site of application, and infrequent.[42]

Common Adverse Effects

The most frequently reported side effects are local skin reactions, occurring in a small percentage of patients [17]:

• Burning, stinging, or pain at the application site
• Itching (pruritus)
• Rash
• Dry skin
• Redness (erythema)
• Tenderness or swelling

Systemic side effects are rare due to minimal absorption but have been reported occasionally, including headache and nausea.[7]

Serious Adverse Effects

While rare, more serious adverse events can occur and warrant immediate medical attention.

• Severe Allergic Reactions: Systemic hypersensitivity reactions, including anaphylaxis, urticaria (hives), angioedema (swelling of the face, lips, tongue, or throat), and generalized rash, have been reported.[42] If signs of a severe allergic reaction such as trouble breathing, severe dizziness, or facial swelling occur, the medication should be discontinued immediately and emergency medical help sought.[42]
• Clostridium difficile-Associated Diarrhea (CDAD): As with nearly all antibacterial agents, CDAD has been reported with Mupirocin use.[52] This severe intestinal condition is caused by an overgrowth of C. difficile bacteria. While the risk is theoretical and extremely low for a topical agent with minimal absorption, it can occur during treatment or even weeks to months after therapy has stopped. Patients who develop persistent, severe diarrhea, abdominal pain or cramping, or blood/mucus in their stool should contact their physician immediately.[50]
• Microbial Overgrowth: Prolonged use of Mupirocin may result in the overgrowth of non-susceptible organisms, including fungi or other bacteria.[32] If a new skin infection develops or the existing one worsens, the medication should be discontinued and alternative therapy instituted.

Contraindications and Warnings

Contraindications

The only absolute contraindication to Mupirocin is a known history of hypersensitivity or allergic reaction to Mupirocin or any of the components in the formulation.[17]

Warnings and Precautions

• Polyethylene Glycol (PEG) Absorption and Renal Impairment: This is a critical, formulation-specific warning. The ointment formulation of Mupirocin contains polyethylene glycol (PEG) as its vehicle.[15] PEG can be absorbed from large open wounds or damaged skin (e.g., extensive burns) and is excreted by the kidneys.[32] In patients with pre-existing moderate to severe renal impairment, the absorption of potentially toxic amounts of PEG can lead to nephrotoxicity.[17] Therefore, Mupirocin ointment should be used with caution or avoided altogether in these specific clinical situations. The cream formulation does not contain PEG and is a safer alternative in these patients.[48]
• Mucosal Use: Mupirocin formulations are not designed for use on mucosal surfaces, with the exception of the nasal ointment for the nares.[49] Intranasal use of the topical ointment (not the nasal formulation) has been associated with stinging and drying.[52]
• Ophthalmic Use: Mupirocin must not be used in the eyes. Accidental contact can cause severe irritation, and the eyes should be rinsed thoroughly with water if this occurs.[39]
• Use at Intravenous Sites: The ointment should not be used with intravenous cannulae or at central IV sites due to the potential to promote fungal infections and antimicrobial resistance.[52]

Drug Interactions

Due to its minimal systemic absorption when applied topically, Mupirocin has no known clinically significant drug-drug interactions.[17] Patients should still inform their healthcare provider of all medications they are taking, but the risk of interaction is extremely low.[56]

Use in Special Populations

The use of Mupirocin in specific patient populations requires careful consideration of the available safety data, which varies by group. The excellent local tolerability and minimal systemic absorption profile generally make it a safe option, but certain caveats apply.

Pregnancy

Mupirocin is classified as Australian TGA Pregnancy Category B1, while the US FDA has phased out its letter category system and has not assigned a new one.[57] The previous US FDA Pregnancy Category was B.[32]

• Clinical Data: There are no adequate and well-controlled studies on the use of Mupirocin in pregnant women.[58] The available data are insufficient to definitively inform on any drug-associated risk for major birth defects or miscarriage.[57]
• Animal Data: Reproduction studies have been performed in rats and rabbits using subcutaneous administration at doses many times higher than the human topical dose. These studies revealed no evidence of harm to the fetus.[32]
• Clinical Recommendation: Because animal reproduction studies are not always predictive of human response, and human data are lacking, Mupirocin should be used during pregnancy only if the potential benefit to the mother clearly outweighs the potential, albeit theoretical, risk to the fetus.[49] Given its minimal systemic absorption (<1%), the risk is considered to be very low.[57] Pregnant individuals should always consult their doctor before use.[60]

Lactation

The use of Mupirocin during breastfeeding is generally considered to be low risk, but specific precautions are advised.[30]

• Excretion in Breast Milk: It is unknown whether Mupirocin is excreted in human milk.[30] However, because systemic absorption in the mother is less than 1%, significant transfer to the infant via breast milk is not expected.[17]
• Effects on Infants: No adverse effects were reported in one case of a nursing infant whose mother was treated with topical Mupirocin along with systemic antibiotics.[30]
• Application to the Breast/Nipple: If Mupirocin is used to treat a cracked or infected nipple, the area must be washed thoroughly with water before breastfeeding to prevent direct ingestion by the infant.[49] For application to the breast, water-miscible cream or gel products are preferred over ointments, as ointments may expose the infant to high levels of mineral paraffins through licking.[30] Studies have shown that Mupirocin is relatively ineffective for treating sore, cracked nipples compared to other therapies.[30]

Pediatrics

Mupirocin is widely used in children, but its safety and efficacy have been established only for specific age groups and formulations.[7]

• Mupirocin Ointment (for Impetigo): Approved for use in pediatric patients aged 2 months and older.[7]
• Mupirocin Cream (for Secondarily Infected Lesions): Approved for use in pediatric patients aged 3 months and older.[7]
• Mupirocin Nasal Ointment (for MRSA Decolonization): Approved for use in adolescents aged 12 years and older.[38]
• Infants Younger than Approved Age: Safety and efficacy have not been established below these age limits.[7] Some international guidelines recommend against use of the ointment in infants under 4 weeks of age.[63]

Parents and caregivers should be instructed on proper application techniques, the importance of completing the full course of treatment, and measures to prevent the spread of infection, such as hand washing and keeping lesions covered.[64]

Geriatrics

• Topical Cream and Ointment: Clinical studies have included elderly patients, and no overall differences in safety or effectiveness have been observed compared to younger adults.[7] No specific geriatric-related problems that would limit its usefulness have been demonstrated.[7]
• Nasal Ointment: A study on decolonizing S. aureus carriers in long-term care facilities, which included many elderly residents (aged 80 and over), found Mupirocin to be effective and did not report significant safety concerns unique to this population.[43]
• General Considerations: No specific dosage adjustments are required for the elderly.[33] However, as with any patient, caution is warranted in those with moderate to severe renal impairment when using the PEG-containing ointment formulation over large, open areas.[31]

Conclusion

Mupirocin remains a uniquely valuable asset in the therapeutic armamentarium against bacterial infections. Its development from a natural product of Pseudomonas fluorescens into a targeted topical antibiotic represents a significant achievement in pharmaceutical science. The drug's distinct mechanism of action, the inhibition of bacterial isoleucyl-tRNA synthetase, provides a critical advantage by circumventing cross-resistance with other antibiotic families, thereby preserving its activity against challenging pathogens like MRSA. This, combined with an exemplary pharmacokinetic profile that maximizes local efficacy while virtually eliminating systemic exposure and its associated risks, establishes Mupirocin as a first-line agent for common superficial skin infections and a cornerstone of MRSA decolonization strategies.

However, the continued success of Mupirocin is profoundly threatened by the inexorable rise of antimicrobial resistance. The global proliferation of high-level, plasmid-mediated resistance (mupA) poses a direct challenge to its efficacy, particularly in the hospital and long-term care settings where it is used most intensively for infection control. The co-location of mupA with other resistance genes on mobile genetic elements means that the use of Mupirocin can inadvertently drive the selection and spread of multi-drug resistant organisms, a sobering reminder of the delicate ecological balance in antimicrobial therapy.

Therefore, the future of Mupirocin hinges on a collective commitment to antimicrobial stewardship. Its use must be guided by evidence, restricted to appropriate clinical indications, and supported by diligent surveillance for emerging resistance. For clinicians, this involves reserving Mupirocin for confirmed or highly suspected staphylococcal and streptococcal infections and implementing targeted, rather than indiscriminate, decolonization protocols. For public health bodies and researchers, the priority must be to monitor resistance trends closely and to explore novel strategies and alternative agents to mitigate the selective pressure on this vital drug. Preserving the efficacy of Mupirocin is not merely about maintaining one therapeutic option; it is about safeguarding a critical tool in the ongoing global battle against antimicrobial resistance.

Works cited

1. CAS 12650-69-0 Mupirocin - BOC Sciences, accessed August 6, 2025, https://bio-fermen.bocsci.com/product/mupirocin-cas-12650-69-0-56590.html
2. Mupirocin - American Chemical Society, accessed August 6, 2025, https://www.acs.org/molecule-of-the-week/archive/m/mupirocin.html
3. Mupirocin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB00410
4. Total Synthesis of (+)-Mupirocin H from d-Glucose | The Journal of Organic Chemistry, accessed August 6, 2025, https://pubs.acs.org/doi/10.1021/jo200396q
5. www.rxlist.com, accessed August 6, 2025, https://www.rxlist.com/mupirocin/generic-drug.htm#:~:text=It%20is%20an%20antibiotic.,%2C%20Bactroban%20Nasal%2C%20and%20Centany.
6. Mupirocin Ointment: Uses & How to Apply - Cleveland Clinic, accessed August 6, 2025, https://my.clevelandclinic.org/health/drugs/20357-mupirocin-cream-or-ointment
7. Mupirocin (topical route) - Side effects & dosage - Mayo Clinic, accessed August 6, 2025, https://www.mayoclinic.org/drugs-supplements/mupirocin-topical-route/description/drg-20064924
8. Mupirocin 12650-69-0 | TCI AMERICA - TCI Chemicals, accessed August 6, 2025, https://www.tcichemicals.com/US/en/p/M2955
9. Mupirocin - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Mupirocin
10. C:\Data\My Documents\CLAY PARK FINAL\NDA 50-788 AP LTR ..., accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50788_Mupirocin_lbl.pdf
11. Mupirocin = 92 HPLC, powder 12650-69-0 - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/m7694
12. Mupirocin | C26H44O9 - ChemSpider, accessed August 6, 2025, https://www.chemspider.com/Chemical-Structure.393914.html
13. Mupirocin | C26H44O9 | CID 446596 - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Mupirocin
14. FDA Advisory No.2021-2023 || Product Recall of Specific Batch of Mupirocin 20 mg/g (2%) Ointment (Mirocid), accessed August 6, 2025, https://www.fda.gov.ph/fda-advisory-no-2021-2023-product-recall-of-specific-batch-of-mupirocin-20-mg-g-2-ointment-mirocid/
15. BACTROBAN mupirocin 2% ointment - NEW ZEALAND DATA SHEET, accessed August 6, 2025, https://www.medsafe.govt.nz/profs/datasheet/b/Bactrobanoint.pdf
16. 50746 Bactroban Cream Microbiology Review - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/50746_BACTROBAN%20CREAM_MICROBR.PDF
17. Mupirocin - StatPearls - NCBI Bookshelf, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK599499/
18. Mupirocin: applications and production - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/30927135/
19. BIOSYNTHESIS OF THE ANTIBIOTIC MUPIROCIN BY ..., accessed August 6, 2025, https://etheses.bham.ac.uk/4204/1/Gurney13PhD.pdf
20. Generic Bactroban Availability - Drugs.com, accessed August 6, 2025, https://www.drugs.com/availability/generic-bactroban.html
21. Mupirocin - Drug Usage Statistics, ClinCalc DrugStats Database, accessed August 6, 2025, https://clincalc.com/drugstats/Drugs/Mupirocin
22. mupirocin - FDA Drug Approval Details - MedPath, accessed August 6, 2025, https://trial.medpath.com/drug/approvals/fda/a1b593e7c95071aa
23. Mupirocin - StatPearls - NCBI Bookshelf, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-159927/
24. Mupirocin Cream USP, 2% - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201587Orig1s000.pdf
25. www.ncbi.nlm.nih.gov, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK599499/#:~:text=Mechanism%20of%20Action,-Mupirocin%2C%20also%20known&text=%5B10%5D%5B11%5D%20Mupirocin,ultimately%20resulting%20in%20cell%20death.
26. 50788 Mupirocin Microbiology Review - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50788_Mupirocin_Microbr.pdf
27. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC180082/
28. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use | Antimicrobial Agents and Chemotherapy - ASM Journals - American Society for Microbiology, accessed August 6, 2025, https://journals.asm.org/doi/10.1128/aac.27.4.495
29. Mupirocin: Package Insert / Prescribing Information - Drugs.com, accessed August 6, 2025, https://www.drugs.com/pro/mupirocin.html
30. Mupirocin - Drugs and Lactation Database (LactMed®) - NCBI ..., accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501429/
31. Mupirocin - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 6, 2025, https://www.pediatriconcall.com/drugs/mupirocin/786
32. Bactroban (Mupirocin) Side Effects, Safety and Risks - Skin Therapy Letter, accessed August 6, 2025, https://www.skintherapyletter.com/drug-profiles/side-effects-2/
33. Bactroban (mupirocin) drug summary - PDR.Net, accessed August 6, 2025, https://www.pdr.net/drug-summary/Bactroban-Ointment-mupirocin-2209
34. Antibacterial activity of mupirocin (pseudomonic acid ... - ASM Journals, accessed August 6, 2025, https://journals.asm.org/doi/pdf/10.1128/aac.27.4.495
35. pubmed.ncbi.nlm.nih.gov, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/26142407/#:~:text=Mupirocin%20resistance%20as%20high%20as,is%20also%20linked%20to%20MDR.
36. Mupirocin Resistance | Clinical Infectious Diseases | Oxford Academic, accessed August 6, 2025, https://academic.oup.com/cid/article/49/6/935/334845
37. Screening for Mupirocin Resistance in Staphylococcus - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4625236/
38. Mupirocin Monograph for Professionals - Drugs.com, accessed August 6, 2025, https://www.drugs.com/monograph/mupirocin.html
39. Mupirocin topical: MedlinePlus Drug Information, accessed August 6, 2025, https://medlineplus.gov/druginfo/meds/a688004.html
40. Review of mupirocin ointment in the treatment of impetigo - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/1468173/
41. Mupirocin: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed August 6, 2025, https://www.medcentral.com/drugs/monograph/6180-388004/mupirocin-topical
42. Addressing Questions Asked by Staff: Safety and Side Effects of Chlorhexidine and Mupirocin - AHRQ, accessed August 6, 2025, https://www.ahrq.gov/sites/default/files/wysiwyg/hai/abate/faqs/faq-safety-chg-mupirocin.pdf
43. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/14614669/
44. Mupirocin Completed Phase 3 Trials for Methicillin Resistant Staphylococcus Aureus Skin Infections Prevention | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB00410/clinical_trials?conditions=DBCOND0038825&phase=3&purpose=prevention&status=completed
45. Methicillin Resistant Staphylococcus Aureus (MRSA) Withdrawn Phase Trials for Mupirocin (DB00410) | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/indications/DBCOND0030654/clinical_trials/DB00410?status=withdrawn
46. Mupirocin: Uses, Side Effects, FAQs & More - GoodRx, accessed August 6, 2025, https://www.goodrx.com/mupirocin/what-is
47. mupirocin topical: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed August 6, 2025, https://www.epocrates.com/online/drugs/436/mupirocin-topical
48. Gainwell Technologies - Therapeutic Class Review, accessed August 6, 2025, https://www.hhs.texas.gov/sites/default/files/documents/october-2024-durb-agenda-item3c.pdf
49. Mupirocin 2% w/w Ointment - Summary of Product Characteristics (SmPC) - (emc) | 3365, accessed August 6, 2025, https://www.medicines.org.uk/emc/product/3365/smpc
50. mupirocin 2 % topical ointment - Kaiser Permanente, accessed August 6, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.mupirocin-2-topical-ointment.269473
51. Mupirocin Topical Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 6, 2025, https://www.drugs.com/dosage/mupirocin-topical.html
52. Mupirocin: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 6, 2025, https://www.rxlist.com/mupirocin/generic-drug.htm
53. Mupirocin topical (Bactroban, Centany) - Uses, Side Effects, and More, accessed August 6, 2025, https://www.webmd.com/drugs/2/drug-6180/mupirocin-topical/details
54. Mupirocin: Pediatric Medication | Memorial Sloan Kettering Cancer Center, accessed August 6, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/pediatric/mupirocin
55. www.rxlist.com, accessed August 6, 2025, https://www.rxlist.com/mupirocin/generic-drug.htm#:~:text=Mupirocin%20has%20no%20known%20interactions,all%20the%20products%20you%20use.
56. Mupirocin topical | Saint Luke's Health System, accessed August 6, 2025, https://www.saintlukeskc.org/health-library/mupirocin-topical
57. Mupirocin topical Use During Pregnancy - Drugs.com, accessed August 6, 2025, https://www.drugs.com/pregnancy/mupirocin-topical.html
58. Is mupirocin (Bactroban) ointment safe to use during pregnancy? - Dr.Oracle, accessed August 6, 2025, https://www.droracle.ai/articles/190903/is-mupirocin-ointment-ok-in-pregnancy
59. www.accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050591s030lbl.pdf
60. Mupirocin - Advanced OB-GYN - Syracuse, NY - Auburn and Central New York| Dr. Myron Luthringer, accessed August 6, 2025, https://www.advancedob-gyn.com/health-library/hw-view.php?DOCHWID=a688004
61. Mupirocin use while Breastfeeding - Drugs.com, accessed August 6, 2025, https://www.drugs.com/breastfeeding/mupirocin.html
62. www.mayoclinic.org, accessed August 6, 2025, [https://www.mayoclinic.org/drugs-supplements/mupirocin-topical-route/description/drg-20064924#:~:text=For%20topical%20dosage%20form%20(cream,be%20determined%20by%20your%20doctor.](https://www.google.com/url?q=https://www.mayoclinic.org/drugs-supplements/mupirocin-topical-route/description/drg-20064924%23:~:text%3DFor%2520topical%2520dosage%2520form%2520(cream,be%2520determined%2520by%2520your%2520doctor.&sa=D&source=editors&ust=1754468644448159&usg=AOvVaw3Odc30LwGRJCPw183dwRPy)
63. Medicianz Mupirocin Ointment - Medsafe, accessed August 6, 2025, https://www.medsafe.govt.nz/consumers/cmi/m/medicianzMupirocinoint.pdf
64. Mupirocin cream/ointment - Perth Children's Hospital, accessed August 6, 2025, https://pch.health.wa.gov.au/~/media/Files/Hospitals/PCH/General-documents/Patients-and-Families/Keeping-our-Mob-Healthy-Health-Facts/Mupirocin-cream-ointment---Keeping-our-Mob-Healthy.pdf